series-a
Stage
2
Investors
About
GC Therapeutics develops off-the-shelf induced pluripotent stem cell (iPSC)-based medicines using its proprietary TFome™ platform to enable scalable, efficient cell therapies targeting gastrointestinal, neurological, and immunological diseases.
Explore GC Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.